Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.68 |
| ▸ | BACE1 | P56817 | 4/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.62 |
| ▸ | CA4 | P22748 | 1/20 | 0.62 |
| ▸ | CA6 | P23280 | 1/20 | 0.62 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 2/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539306 | 1.00 | GSK3B (0.68) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL14021580 | 0.91 | NR1H4 (0.60) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL15687588 | 0.90 | LMNA (0.77) | GSK3BBACE1CA12CA7CA9 | |
| SCHEMBL15687587 | 0.90 | LMNA (0.77) | GSK3BBACE1CA12CA7CA9 | |
| SCHEMBL13791103 | 0.90 | KDM4E (0.56) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL8317285 | 0.89 | GSK3B (0.55) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL3923014 | 0.88 | GSK3B (0.64) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL1563532 | 0.88 | FFAR1 (0.55) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL14039572 | 0.88 | FFAR1 (0.55) | GSK3BBACE1NR1H4CA12CA7 | |
| SCHEMBL13678668 | 0.88 | ALDH1A1 (0.55) | GSK3BBACE1NR1H4CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| EP-0779808-B1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION YHTYMAE OY (FI) | 1999-08-18 | — | — | EP | disclosed |
| US-5912273-A | COMPOUNDS WITH CHLORO AND HYDROXY GROUPS FOR OSTEOPOROSIS | ORION-YHTYMA OY (FI) | 1999-06-15 | — | — | US | disclosed |
| US-5750576-A | BONE DISORDERS | ORION-YHTYMA OY (FI) | 1998-05-12 | — | — | US | disclosed |
| EP-0779808-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ORION-YHTYMÄ OY (FI) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007402-A1 | TRIPHENYLETHYLENES FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | Orion-Yhtymä Oy (FI) | 1996-03-14 | — | — | WO | disclosed |
| EP-0071399-A2 | Substituted pyrrolidine cardiovascular system regulators and antihypertensives, their preparation and use | SYNTEX (U.S.A.) INC. (US) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | GSK3B 806/4885BACE1 540/4885NR1H4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.